How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause

    Closed for comments This consultation ended on at   Request commenting lead permission

    1 Draft recommendations

    1.1 Evidence on the safety and efficacy of removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause is inadequate in quality and quantity. Therefore, this procedure should not be done unless it is part of a formal research study, with appropriate governance and ethics approval. Find out what only in research means on the NICE interventional procedures guidance page.

    1.2 Research should include randomised controlled trials and should report details of:

    • patient selection

    • the procedure, including the techniques used for harvesting tissue and cryopreservation, the timing and the frequency of reimplantation of ovarian tissue, the association between the amount of tissue removed and reimplanted and subsequent endocrine function

    • a comparator group who have pharmacological hormone replacement therapy (HRT).

    1.3 Patient selection should be done by a multidisciplinary team including clinicians with specialist expertise in managing the menopause.

    1.4 The procedure should only be done by surgeons with specialist expertise in the procedure.